Delayed SEC reports
Compare what managers reported this quarter with last quarter. These reports are delayed.Large US investment managers report many holdings every quarter. We compare the shares they reported this quarter with the prior quarter. The reports arrive late and do not show the exact trade day, trade price, shorts, cash, or the manager’s reason.
10 of 16 managers have a matching row in their newest complete report.
$875.10 B total reported value across 13575 holdings · 13F-HR · filed Aug 14, 2026 · open SEC report ↗
How to read this manager
Citadel often reports shares, calls, and puts at the same time. These rows show reported exposure, not a simple bullish or bearish bet.
TickerYou therefore keeps this manager out of the group direction ranking, while preserving its common-share and option rows here for investigation.
These managers' newest complete report is at least 2 quarters behind the newest period above. They remain available for history, but are kept separate from managers with newer reports.
For the matching rows, compared with Q1 2026, the Q2 2026 report's stock rows show 65 new positions, 101 positions with more shares reported, 92 positions with fewer shares reported, and 40 positions that no longer appear.
Green + ▲ means new or more shares; red + ▼ means fewer shares or no longer listed. The words and dot count repeat the meaning without relying on colour. Fewer shares or no listing does not mean the manager opened a short position.
Kept outside those common-share counts: 393 option-contract rows, 7 principal-amount positions.
13F reports can arrive up to 45 days after quarter-end, so this comparison is not proof of when, why, or at what price the manager traded.
Green means the manager reported a new or larger share amount. Red means a smaller amount or the stock was no longer listed. This compares two delayed reports; it does not show the exact trade.
Biggest reported changes — ranked by position value. The bar is the position's size against the largest one shown; the figure under it is the difference in the filed SH or principal amount. Corporate actions are not normalized.
Absent from latest filing — a 13F reports only that the position is absent, not when, why, or for what proceeds it changed. The prior SH or principal amount is printed, but these rows are not ranked because those units are not comparable.
PUT and CALL are contract labels, not common-share holdings. A 13F reports these option rows but does not establish whether the strategy is bullish, bearish, hedged, or part of a spread. It also does not reveal strike, expiry, premium, or the rest of the manager's book.
383 more option comparison rows in this filing.
These rows use PRN amounts, not share counts, and are excluded from common-share comparisons.
| Position | Value | Filed amount | Change |
|---|---|---|---|
| $1.2 M0.0% of filing | 717,686 sh | NEW THIS QUARTER | |
| $1.2 M0.0% of filing | 81,971 sh | FEWER SHARES | |
| $1.1 M0.0% of filing | 695,890 sh | MORE SHARES | |
| $1.0 M0.0% of filing | 145,870 sh | MORE SHARES | |
| $989,0260.0% of filing | 1,009,107 sh | MORE SHARES | |
| $922,9160.0% of filing | 25,751 sh | NEW THIS QUARTER | |
| $921,9730.0% of filing | 198,701 sh | FEWER SHARES | |
| $909,7450.0% of filing | 67,639 sh | FEWER SHARES | |
| $874,2260.0% of filing | 13,172 sh | NEW THIS QUARTER | |
| $868,5940.0% of filing | 48,688 sh | NEW THIS QUARTER | |
SEC issuerCORBUS PHARMACEUTICALS HLDGS | $864,4050.0% of filing | 92,154 sh | FEWER SHARES |
| $850,9340.0% of filing | 215,973 sh | NEW THIS QUARTER | |
| $844,3200.0% of filing | 796,529 sh | FEWER SHARES | |
| $807,5760.0% of filing | 379,144 sh | MORE SHARES | |
| $793,9100.0% of filing | 349,740 sh | MORE SHARES | |
| $778,7490.0% of filing | 334,227 sh | NEW THIS QUARTER | |
| $775,0510.0% of filing | 158,822 sh | FEWER SHARES | |
| $763,5940.0% of filing | 71,032 sh | FEWER SHARES | |
SEC issuerVIRIDIAN THERAPEUTICS INC | $758,7360.0% of filing | 41,303 sh | FEWER SHARES |
| $741,3050.0% of filing | 50,844 sh | FEWER SHARES | |
| $731,0920.0% of filing | 157,224 sh | MORE SHARES | |
| $716,7810.0% of filing | 895,864 sh | FEWER SHARES | |
| $621,7370.0% of filing | 85,053 sh | NEW THIS QUARTER | |
SEC issuerNEUBERGER BERMAN ETF TRUST | $582,5250.0% of filing | 15,710 sh | FEWER SHARES |
SEC issuerLINEAGE CELL THERAPEUTICS IN | $558,2820.0% of filing | 426,169 sh | MORE SHARES |